iPSC-derived T cells and macrophages: Manufacturing and next-generation application approaches

Area of Science:

• Immunotherapy
• Stem Cell Biology
• Oncology

Background:

• Chimeric antigen receptor (CAR) technology shows promise in treating blood cancers but faces limitations in solid tumors, scalability, and donor variability.
• Induced pluripotent stem cell (iPSC) technology offers a renewable and adaptable source for developing CAR-based therapies.
• Current CAR therapies often rely on autologous or allogeneic sources, presenting challenges in manufacturing and accessibility.

Purpose of the Study:

• To review recent advancements in iPSC-derived CAR-T cells and CAR-macrophages for cancer immunotherapy.
• To discuss strategies for differentiation, genetic engineering, and mitigating immune rejection (Graft-versus-Host Disease).
• To explore the potential of iPSCs in generating diverse immune cell populations for broader therapeutic applications.

Main Methods:

• Review of current literature on iPSC differentiation protocols for immune cells.
• Analysis of gene engineering techniques for CAR expression in iPSC-derived cells.
• Examination of strategies to address histocompatibility and immune compatibility.

Main Results:

• iPSCs provide a scalable, off-the-shelf source for CAR-T and CAR-macrophage therapies.
• Development of protocols for generating iPSC-derived immune cells, including T cells, macrophages, and less common populations like NKT and microglial cells.
• Strategies for mitigating Graft-versus-Host Disease (GvHD) and overcoming histocompatibility barriers are advancing.

Conclusions:

• iPSC-derived CAR therapies represent a significant advancement in overcoming limitations of current immunotherapies.
• These therapies hold potential for treating solid tumors and enhancing accessibility to specialized immune cell products.
• Further research and clinical validation are needed to fully realize the potential of iPSC-based cancer treatments.